An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
Top Cited Papers
- 30 April 2007
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 143 (4), 566-583.e2
- https://doi.org/10.1016/j.ajo.2007.01.028
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose StudyOphthalmology, 2006
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinAmerican Journal of Ophthalmology, 1999